Glucocorticoid

Secondary prevention of CVD with colchicine is a major focus for the cardiology community, especially after recent presentations of the COLCOT and COLCHICINE-PCI trials at the American Heart Association Scientific Sessions in November.

Glucocorticoid treatments contribute to organ damage accrual in patients with systemic lupus erythematosus, independent of clinical or serological disease activity, according to data published in The Lancet Rheumatology.

Higher glucocorticoid doses for adults with congenital adrenal hyperplasia may be associated with lower bone mineral density, especially among women and those prescribed prednisolone, according to findings published in Clinical Endocrinology.

ATLANTA — Approximately 47% of patients in clinical remission after receiving 1 year of weekly tocilizumab for giant cell arteritis maintained their treatment-free remission for an additional 2 years, according to a speaker at the 2019 ACR/ARP Annual Meeting.

ATLANTA — Increased use of glucocorticoid-sparing agents is one of the key recommendations in a guideline document that covers seven vasculitis diseases, according to a speaker at ACR/ARP 2019.

ATLANTA — The 2019 iteration of the ACR/ARP Great Debate tackled the issue of whether anabolic therapies are appropriate for patients with glucocorticoid-induced osteoporosis.

ATLANTA — Treatment with repeat doses of rituximab is superior to daily azathioprine for preventing relapse among patients with ANCA-associated vasculitis with a history of relapse, according to data presented at the 2019 ACR/ARP Annual Meeting.

SAN DIEGO — Increasing use of checkpoint inhibitors in cancer therapy is leading to an uptick in immune-related adverse events for rheumatologists to manage, according to a presentation at the Congress of Clinical Rheumatology West.

In a new study published in The New England Journal of Medicine, nearly half of black children with uncontrolled asthma fared better with an increased dose of glucocorticoids, as compared with the addition of a long-acting beta agonist to low-dose glucocorticoids.

Herpes zoster (HZ) continues to be a relevant public health issue because of its prevalence and potential complications. It is estimated that one out of three people in the United States will develop HZ in their lifetime. Varicella zoster virus, the cause of HZ, is one of eight herpes viruses that infect humans.